- Home
- CHH vs BPMC Comparison
CHH vs BPMC Comparison
Compare CHH & BPMC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHH
- BPMC
- Stock Information
- Founded
- CHH 1939
- BPMC 2008
- Country
- CHH United States
- BPMC United States
- Employees
- CHH N/A
- BPMC N/A
- Industry
- CHH Hotels/Resorts
- BPMC Biotechnology: Pharmaceutical Preparations
- Sector
- CHH Consumer Discretionary
- BPMC Health Care
- Exchange
- CHH Nasdaq
- BPMC Nasdaq
- Market Cap
- CHH 5.8B
- BPMC 5.8B
- IPO Year
- CHH 1997
- BPMC 2015
- Fundamental
- Price
- CHH $122.88
- BPMC $128.20
- Analyst Decision
- CHH Hold
- BPMC Buy
- Analyst Count
- CHH 14
- BPMC 20
- Target Price
- CHH $133.64
- BPMC $127.82
- AVG Volume (30 Days)
- CHH 402.3K
- BPMC 6.4M
- Earning Date
- CHH 08-07-2025
- BPMC 07-31-2025
- Dividend Yield
- CHH 0.94%
- BPMC N/A
- EPS Growth
- CHH 40.19
- BPMC N/A
- EPS
- CHH 6.57
- BPMC N/A
- Revenue
- CHH $797,663,000.00
- BPMC $562,121,000.00
- Revenue This Year
- CHH $103.49
- BPMC $44.46
- Revenue Next Year
- CHH $3.35
- BPMC $32.78
- P/E Ratio
- CHH $18.54
- BPMC N/A
- Revenue Growth
- CHH N/A
- BPMC 99.19
- 52 Week Low
- CHH $116.13
- BPMC $73.04
- 52 Week High
- CHH $157.86
- BPMC $128.34
- Technical
- Relative Strength Index (RSI)
- CHH 41.14
- BPMC 75.62
- Support Level
- CHH $121.42
- BPMC $127.86
- Resistance Level
- CHH $131.40
- BPMC $128.33
- Average True Range (ATR)
- CHH 2.82
- BPMC 0.41
- MACD
- CHH -0.57
- BPMC -0.32
- Stochastic Oscillator
- CHH 15.14
- BPMC 84.62
About CHH Choice Hotels International Inc.
As of Dec. 31, 2024, Choice Hotels operated 654,000 rooms across the economy, midscale, upscale, and extended-stay segments. Comfort Inn and Comfort Suites are the largest brands (26% of the company's total domestic rooms), while Ascend and Cambria (10% of total domestic rooms) are newer lifestyle and select-service brands. Choice closed on its Radisson acquisition in August 2022, which added about 70,000 rooms. Franchises account for 100% of total revenue, and the United States represent 78% of total rooms in 2024.
About BPMC Blueprint Medicines Corporation
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer.